October 2010 Issue of MMM
Last month, I began this column by revealing what seemed like the first piece of good news in a long time--namely, that the average paycheck ...
Pfizer is investing heavily in adherence, putting patient support programs on equal footing with some of its drugs, Matthew Arnold reports
Industry experts discuss definitions of success in patient education—and ways to measure its value. James Chase takes the chair
Something good's going on. Professional journal advertising has rebounded in spectacular fashion in the first-half 2010. James Chase reports on the biggest advertisers and most ...
When Paul Thacker announced in July that he was leaving the Senate Finance Committee, you could practically hear drug company lobbyists whooping for joy.
Targeted cancer therapies and chemotherapeutic products are a $20 billion category. Expanding indications for marketed products and a bulging pipeline should keep this segment growing ...
The best sales messages are relevant and address customers' needs. But how does a brand team create such messages if they don't understand who their ...
There is a lot of confusion about this year's flu vaccine, in part because last year's novel H1N1 mild flu pandemic broke the usual mold ...
A new report whose findings could have profound implications for adverse events reporting says patients began discussing the risks of GlaxoSmithKline diabetes drug Avandia in ...
Novartis is bucking the trend toward fewer sales calls to healthcare professionals.
Featuring news about Shire, Love and Other Drugs, Procter & Gamble and Somaxon Pharmaceuticals
Med Ed Report
While the number of physicians open to pharmaceutical sales calls is shrinking, a new survey suggests some venues are more hospitable to industry than others.
Lighthouse Learning is offering to produce CME content that is free of commercial support.
The Board of the Accreditation Council for CME approved a new process for handling complaints on accredited providers, in which those that break the rules ...
Featuring news about the AMA, Ascend Integrated Media, Archives of Internal Medicine, Nexus Communications and the American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) and Harborside Press launched the inaugural print issue of ASCO Post in June, and launched a website home ...
Quadrant HealthCom united two titles--The Female Patient and OBG Management--under an alliance providing advertisers with a "ping-pong" opportunity for campaigns.
Featuring news about JAMA, Columbia University, FDA, Division of Durg Marketing, Advertising and Communication and Baxter
Sen. Chuck Grassley released a report shedding light on the controversial practice of ghostwriting. Some say his findings are based on outdated publication-planning practices. How ...
Online drug ads are significantly more helpful this year, particularly with respect to side effect and safety information, according to an About.com survey of its ...
Marketing firm QualityHealth says a partnership with website iVillage will potentially expose more women to its pharma-sponsored content while giving clients better control over DTC ...
Featuring news about Novo Nordisk, WebMD, Medscape and Nationwide Children's Hospital
The fall magazines are always fat with ads, and the latest issues of People were no exception. I was happy to spot many DTC ads ...
Golf legend and prostate cancer survivor Arnold Palmer is the celebrity face of a new educational website and program developed by Centocor Ortho Biotech and ...
Drug ads emphasizing familial health risks prompt at-risk patients to adjust their lifestyles, not just pop a pill, a study found.
An agency said a survey of 1,500 Americans with one or more metabolic disorders revealed four behavioral types common across diabetes, obesity and other conditions.
A fifth of consumers have asked their doctor to prescribe a drug they learned about through advertising, and fully two-thirds have received free samples of ...
Featuring news about Novo Nordisk, CannaCare and American Cancer Society Cancer Action Network
AARP, which has taken heat for omitting rebates and discounts from its old "Rx Watchdog" pricing reports, said it found such discounts do little to ...
With a race on to develop a new obesity treatment, Ipsos surveyed primary care doctors and found receptivity to all three clinical-stage products.
The agency formerly known as LyonHeart is going back to its maiden name ahead of the rollout of a new Omnicom healthcare agency network.
Pfizer Consumer Healthcare awarded McGarryBowen another big Pfizer account, handing the shop the bulk of its heavily advertised Advil business following a competitive pitch.
Featuring news about inVentiv Health, Sustrat'Homme SA, APCO Worldwide, Waggener Edstrom, Dendreon and Publicis
That Britain is proposing the most radical reorganization of the National Health Service (NHS) since its establishment in 1948 is significant and sobering--but not surprising.
A new HHS report, The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs, calls for a new ...
Two breast cancer treatment advocacy groups have written to FDA asking that the agency refrain from changing the approved labeling for Genentech's Avastin.
When was the last time you took a good, hard look at the ads in some of the regular journals you receive?
By now, you've probably heard about FTC efforts to ban reverse-payment patent settlements. FTC chairman Jon Leibowitz claims pharma-generic company deals are among "the most ...
In the 1990s, brand-based DTC advertising was a big breakthrough innovation in pharmaceutical marketing.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.